WO2009101604A3 - Recombinant lumpy skin disease virus for preventing aids - Google Patents

Recombinant lumpy skin disease virus for preventing aids Download PDF

Info

Publication number
WO2009101604A3
WO2009101604A3 PCT/IB2009/050624 IB2009050624W WO2009101604A3 WO 2009101604 A3 WO2009101604 A3 WO 2009101604A3 IB 2009050624 W IB2009050624 W IB 2009050624W WO 2009101604 A3 WO2009101604 A3 WO 2009101604A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
recombinant
hiv
skin disease
lsd
Prior art date
Application number
PCT/IB2009/050624
Other languages
French (fr)
Other versions
WO2009101604A2 (en
Inventor
Anna-Lise Williamson
Nicola Douglass
Yen-Ju Shen
Original Assignee
South African Medical Research Council
University Of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South African Medical Research Council, University Of Cape Town filed Critical South African Medical Research Council
Publication of WO2009101604A2 publication Critical patent/WO2009101604A2/en
Publication of WO2009101604A3 publication Critical patent/WO2009101604A3/en
Priority to ZA2010/03806A priority Critical patent/ZA201003806B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention describes a method of manufacturing a recombinant nucleic acid molecule and virus for delivering one or more HIV antigens to a subject, the method including the step of inserting one or more human immunodeficiency virus (HIV) sequences into a lumpy skin disease (LSD) virus nucleotide sequence or virus. The HIV sequences are capable of being expressed from the LSD virus sequence as one or more HIV proteins or immunogenic parts thereof. Recombinant LSD nucleic acid molecules and viruses are also described. Pharmaceutical compositions including the recombinant virus may be used for the inhibition of AIDS in a human.
PCT/IB2009/050624 2008-02-14 2009-02-16 Recombinant lumpy skin disease virus for preventing aids WO2009101604A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ZA2010/03806A ZA201003806B (en) 2008-02-14 2010-05-27 Recombinant lumpy skin disease virus for preventing aids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2008/01508 2008-02-14
ZA200801508 2008-02-14

Publications (2)

Publication Number Publication Date
WO2009101604A2 WO2009101604A2 (en) 2009-08-20
WO2009101604A3 true WO2009101604A3 (en) 2009-11-12

Family

ID=40853835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/050624 WO2009101604A2 (en) 2008-02-14 2009-02-16 Recombinant lumpy skin disease virus for preventing aids

Country Status (2)

Country Link
WO (1) WO2009101604A2 (en)
ZA (1) ZA201003806B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
GB2573791A (en) * 2018-05-17 2019-11-20 Univ Cape Town Stabilised superoxide dismutase (SOD) homolog gene and uses thereof
CN116947981B (en) * 2023-07-07 2024-04-23 华中农业大学 LSDV and GTPV universal diagnostic antigen, monoclonal antibody thereof and application

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASPDEN KATE ET AL: "Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector.", THE JOURNAL OF GENERAL VIROLOGY AUG 2003, vol. 84, no. Pt 8, August 2003 (2003-08-01), pages 1985 - 1996, XP002544352, ISSN: 0022-1317 *
BURGERS W A ET AL: "Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 87, no. 2, 1 January 2006 (2006-01-01), pages 399 - 410, XP002423823, ISSN: 0022-1317 *
DATABASE EMBL 4 September 2002 (2002-09-04), XP002544354, retrieved from EBI Database accession no. AF409138 *
WILLIAMSON ANNA-LISE: "The development of HIV-1 subtype C vaccines for Southern Africa.", IUBMB LIFE 2002 APR-MAY, vol. 53, no. 4-5, April 2002 (2002-04-01), pages 207 - 208, XP002544353, ISSN: 1521-6543 *

Also Published As

Publication number Publication date
WO2009101604A2 (en) 2009-08-20
ZA201003806B (en) 2011-08-31

Similar Documents

Publication Publication Date Title
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
BRPI0922867B8 (en) respiratory syncytial virus (rsv) fusion glycoprotein (f), isolated nucleic acid, host cell, vaccine composition and purified micelle
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2007024941A3 (en) Polyvalent vaccine
WO2008052770A3 (en) (base-)modified rna for increasing the expression of a protein
WO2008092854A3 (en) Papillomavirus e2 polypeptide used for vaccination
WO2007144317A3 (en) Vaccine
WO2010141511A3 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2008079372A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2008083949A3 (en) Rna-coded antibody
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
WO2005118813A3 (en) Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2006123256A3 (en) Hivcon: an hiv immunogen and uses thereof
WO2008011636A3 (en) Targeted gene delivery for dendritic cell vaccination
WO2007124327A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
WO2010019262A3 (en) Polyvalent vaccine
WO2009068992A8 (en) Vaccination with multiple clades of h5 influenza a virus
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2009090639A3 (en) Sirna compounds and methods of use thereof
ZA201001556B (en) Polyethylene glycol modified interferon alpha 2b and preparation method and applications thereof
WO2009080806A3 (en) Modified influenza virus
WO2011072292A3 (en) Phase changing formulations of rna and rna derivatives
WO2009080715A3 (en) Vaccines for malaria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09710425

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09710425

Country of ref document: EP

Kind code of ref document: A2